Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
pharmaceutical investing Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
Element79 Gold Corp Announces Corporate Update and Strategic Leadership Changes With Focus On Accelerating Nevada Asset Development
